BLM (anti-BLyS) is a fully human monoclonal IgG1 Ab (the first approved for the treatment of SLE) that binds soluble BLyS and inhibits its binding to TACI, BCMA, and BAFF-R [16]. The gene discussed is TNFRSF13C; the disease is systemic lupus erythematosus.